- TFX Ticker
- 🇺🇸 NYSE Exchange
- 15,200 Employees
- 💊 Health Care Sector
- 🩺 Health Care Equipment & Supplies Industry
- Liam J. Kelly CEO
Financial statements — Teleflex
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|
Total Revenue |
|
2.5B | 2.6B | 2.4B | 2.1B | 1.9B |
Cost Of Revenue |
|
1.2B | 1.1B | 1.1B | 970M | 870M |
Gross Profit |
|
1.3B | 1.5B | 1.4B | 1.2B | 1M |
Research and Development |
|
120M | 110M | 110M | 85M | 59M |
Selling General and Admin |
|
740M | 930M | 880M | 700M | 560M |
Operating Expense |
|
2.1B | 2.2B | 2B | 1.8B | 1.5B |
Operating Income |
|
460M | 440M | 400M | 390M | 370M |
Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
EBIT |
|
460M | 440M | 400M | 390M | 370M |
Interest Income |
|
65M | 79M | 100M | 82M | 54M |
Pretax Income |
|
360M | 340M | 220M | 280M | 250M |
Income Tax |
|
22M | -120M | 23M | 130M | 8.1M |
Minority Interest |
|
0 | 0 | 0 | 0 | 460K |
Net Income |
|
340M | 460M | 200M | 150M | 240M |
Net Income Basic |
|
340M | 460M | 200M | 150M | 240M |
20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|
Current cash |
|
380M | 300M | 360M | 330M | 540M |
Short term investments |
|
140M | 110M | 85M | 54M | 49M |
Receivables |
|
400M | 420M | 370M | 350M | 270M |
Inventory |
|
510M | 480M | 430M | 400M | 320M |
Other current assets |
|
140M | 110M | 85M | 54M | 49M |
Current assets |
|
1.4B | 1.3B | 1.2B | 1.1B | 1.2B |
Long term investments |
|
5.7B | 5B | 5B | 5.1B | 2.7B |
Property plant equipment |
|
470M | 430M | 430M | 380M | 300M |
Goodwill |
|
2.6B | 2.2B | 2.2B | 2.2B | 1.3B |
Intangible assets |
|
2.5B | 2.2B | 2.3B | 2.4B | 1.1B |
Other assets |
|
42M | 52M | 35M | 47M | 35M |
Total assets |
|
7.2B | 6.3B | 6.3B | 6.2B | 3.9B |
Accounts payable |
|
100M | 100M | 110M | 92M | 69M |
Current long term debt |
|
100M | 50M | 87M | 87M | 180M |
Other current liabilities |
|
340M | 410M | 390M | 310M | 180M |
Total current liabilities |
|
540M | 560M | 580M | 480M | 430M |
Long term debt |
|
2.4B | 1.9B | 2.1B | 2.2B | 850M |
Other liabilities |
|
330M | 370M | 480M | 500M | 200M |
Minority Interest |
|
0 | 0 | 0 | 0 | 0 |
Total Liabilities |
|
3.8B | 3.3B | 3.7B | 3.8B | 1.8B |
Common stock |
|
46M | 46M | 46M | 45M | 43M |
Retained earning |
|
3.1B | 2.8B | 2.4B | 2.3B | 2.2B |
Treasury stock |
|
-160M | -170M | -170M | -230M | -170M |
Capital surplus |
|
• | • | • | • | • |
Shareholder equity |
|
3.3B | 3B | 2.5B | 2.4B | 2.1B |
Net tangible assets |
|
-1.8B | -1.4B | -2B | -2.2B | -230M |
20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|
Net Income |
|
340M | 460M | 200M | 150M | 240M |
Depreciation |
|
230M | 210M | 210M | 160M | 120M |
Changes in receivables |
|
-24M | 52M | 20M | 74M | 9.6M |
Changes in inventories |
|
37M | 49M | 32M | 80M | -14M |
Cash change |
|
75M | -56M | 24M | -210M | 210M |
Cash flow |
|
440M | 440M | 440M | -6.4M | 410M |
Capital expenditures |
|
-91M | -100M | -81M | -71M | -53M |
Investments |
|
• | • | • | • | • |
Investing activity other |
|
• | • | • | • | • |
Total investing cash flows |
|
-840M | -73M | -200M | -1.8B | -57M |
Dividends paid |
|
• | • | • | • | • |
Net borrowings |
|
2B | 1.5B | 1.7B | 1.9B | 440M |
Other financing cash flows |
|
• | • | • | • | • |
Cash flow financing |
|
460M | -420M | -210M | 1.1B | -120M |
Exchange rate effect |
|
• | • | • | • | • |
Analyst Recommendations
This chart is a recommendation for investors. To provide forecasts, analysts and brokers use companies' public financial reports and speak with their employees and clients. The end result is a solution that's marked on the chart, which shows analysts' opinions at different periods of time. Move your cursor to track on what the dates the recommendations changed.
Investors shouldn't only follow analyst recommendations. Forecasts should be used to supplement existing strategies and plans. Trading based on a recommendation chart is is considered bad practice. Analyst reports should only be used in conjunction with your own analytics.
Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, the Middle East and Africa (EMEA), Asia and Original Equipment Manufacturer and Development Services (OEM). The Vascular North America segment products facilitate a variety of critical care therapies, including the administration of intravenous medications and other therapies and the measurement of blood pressure and taking of blood samples through a single puncture site. The Interventional North America segment is comprised of the North American component of Vascular Solutions business. The Anesthesia North America segment provides products for clinicians working primarily in emergency rooms, surgery and critical care settings. The Surgical North America segment products are predominantly comprised of single-use products, including ligation clips and closure products; appliers and sutures used in a variety of surgical procedures; access ports used in minimally invasive laparoscopic surgical procedures, including robotic surgery, and fluid management products used for chest drainage. The EMEA segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves two end markets: hospitals and healthcare providers, and home health. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. Teleflex was founded in 1943 and is headquartered in Wayne, PA.